secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2026-10-23T14:31:29+00:00
Accession:  0001193125-26-429647
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 5.03, 1.02, 2.01, 3.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Bolt Biotherapeutics acquires Prana in reverse merger; raises $120M PIPE, Prana holders to own 51.7% post-financing
--------------------------------------------------------------------------------

- Bolt acquired Prana on Oct. 23, 2026; Prana holders received 430,746 BOLT shares plus 16,360.929 Series D preferred shares convertible into 1,000 common each.
- Pre-transaction Bolt holders fall to ~11.8% pre-financing and ~6.9% post-financing; Prana holders ~88.2% then ~51.7%; PIPE investors ~41.4%.
- $120M PIPE sale of 13,995.311 Series D preferred shares plus warrants for 50% more, expected to close Oct. 26, 2026; full warrant exercise would add ~$60M gross.
- Series D pays as-if-converted dividends, has no general voting rights but must approve specified actions; votes cover conversion, Nasdaq proposals, charter amendment, 1:2-1:12 reverse split.
- Lease termination triggers $4.5M payment to HCP LS Redwood City; Dr. Sheila Gujrathi joins board and becomes Chief Strategy Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000119312526429647/0001193125-26-429647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000119312526429647/bolt-20261023.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-429647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer